依达拉奉联合尿激酶静脉溶栓治疗急性脑梗死的临床效果观察

目的 使用依达拉奉联合尿激酶静脉溶栓治疗急性脑梗死患者,对其效果进行观察。方法 对滑县人民医院2016年2月—2017年5月收治的87例急性脑梗死患者分组研究,随机分成研究组(n=44)与参照组(n=43),参照组行尿激酶静脉溶栓治疗,研究组在此基础上联合依达拉奉治疗,比较并分析两组治疗结果。结果 2组治疗前炎性因子水平相比,差异无统计学意义(P>0.05),研究组治疗后hs-CRP、TNF-α水平与参照组相比,相对更低(P<0.05);两组治疗前NIHSS、ADL评分相比,组间差异无统计学意义(P>0.05),观察组治疗后NIHSS评分低于参照组(P<0.05),观察组ADL评分低于参照组(P<0.05);研究组总有效率为93.18%,高于参照组的72.09%(P<0.05)。结论 对急性脑梗死患者应用依达拉奉联合尿激酶静脉溶栓治疗效果较好,可缓解患者神经功能缺损程度,减轻炎症反应,提升其日常生活能力,值得推广应用。

Clinical effect of edaravone combined with urokinase intravenous thrombolysis in treatment of acute cerebral infarction

Objective To investigate the clinical effect of edaravone combined with urokinase intravenous thrombolysis in the treatment of acute cerebral infarction. Methods A total of 87 patients with acute cerebral infarction admitted to Huaxian People's Hospital from February 2016 to May 2017 were randomly divided into a trial group (n=44) and a control group (n=43). The control group was treated with urokinase intravenous thrombolysis, and on this basis, the trial group was treated with edaravone, and the results of the two groups were analyzed and compared. Results There was no significant difference between the two groups before the treatment in the levels of inflammatory factors (P>0.05). After the treatment, the levels of hs-CRP and TNF-alpha in the trial group were lower than those in the control group (P<0.05). There was no significant difference in NIHSS and ADL scores between the two groups before the treatment (P>0.05). After the treatment, the NIHSS scores in the trial group were lower than those in the control group (P<0.05), and the ADL scores in the trial group were lower than those in the control group (P<0.05). The total effective rate was 93.18% in the trial group, which was higher than that (72.09%) in the control group (P<0.05). Conclusion Edaravone combined with urokinase intravenous thrombolysis is effective in the treatment of acute cerebral infarction. It can alleviate the degree of neurological deficit, alleviate inflammation and improve the ability of daily living of patients with acute cerebral infarction. It is worthy of popularizing and applying.